Accera announced it has recently closed a Series C financing round of $35 million (euro 27 million), led by Inventages Venture Capital SA. The company says that the proceeds of this financing will be used to begin sales and marketing ofthe company’s lead product, Axona(TM) (previously known as Ketasyn), which as the company says, is “scheduled to launch in the United States in the first quarter of 2009.”
Can somebody explain to me how it is possible to launch a drug without having released results of a single phase 3 trial or have filed an NDA? Anybody?
Accera, Inc. Completes $35 Million Series C Financing
-(Via PR Newswire: Biotechnology.)
Theoretically Related Posts
This post was constructed by .
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Add New Comment
Viewing 1 Comment
Thanks. Your comment is awaiting approval by a moderator.
Do you already have an account? Log in and claim this comment.
Do you already have an account? Log in and claim this comment.
Add New Comment
Trackbacks
(Trackback URL)